The thirteenth Applied Pharmacoeconomics and Outcomes Research Forum was held February 6th, 2017 at the University of California San Diego, Faculty Club. The event was hosted by the Skaggs School of Pharmacy and Pharmaceutical Sciences and supported by contributions to the PE Forum Sponsorship Fund and Exhibitors. Thank you to our sponsors and exhibitors!

The topic for the Forum was “The New World of Biosimilars in the U.S.: Current Challenges to Inform Future Directions”.

Continuing our theme of kicking off the Forum by testing the audience knowledge we challenged participants with a series of trivia questions related to “Biosimilars” of the Animal Kingdom (commonly confused animals that look similar).

What are these? Which guards herds of the other? Which is sweater worthy?

Answers to these questions and 7 more “Biosimilar” Animal Pairs, can be found in the PE Forum Introductory slide set posted along with the speaker slides at the link below.

http://pharmacy.ucsd.edu/faculty/pharmacoeconomics_forum.shtml

SPEAKERS

Biosimilars: Are we there yet?  
Charles Daniels, PhD, Pharmacist-in Chief, UCSD Health

Stakeholder Perspectives

Pharmaceutical Manufacturer – Innovator and Biosimilar Products  
Scott Foraker, JD, Vice President and General Manager, Biosimilars, Amgen

Health Care System  
Ambrose Carrejo, PharmD, Director, National Pharmaceutical Contracting, Kaiser Permanente

Health Plan  
Mark Cziraky, PharmD, VP Research HealthCore, an Anthem Company
Purpose of Applied Pharmacoeconomic and Outcomes Research Forums

The number of individuals in the Southern California region with interest in pharmacoeconomics (PE) is growing rapidly across the healthcare system - from those involved with creation of PE data within pharmaceutical and biotech companies to those incorporating results into decision making within a plethora of managed care organizations. The region provides an excellent opportunity to gather individuals to debate issues, and propose solutions that are vetted from multiple perspectives – not just individual silos defined by employer.

The Applied Pharmacoeconomic and Outcomes Research Forum was created to facilitate this cross perspective communication. The goals of the forum are to:
1. Discuss commonly encountered obstacles to conducting or utilizing results of applied pharmacoeconomic studies and explore solutions from various perspectives of the health care system.
2. Create an environment and foundation to foster the creation of a Southern California Pharmacoeconomic and Outcomes Research Interest Group

PAST FORUM TOPICS
1. AMCP Dossiers: Useful for Decision Making or Not? A Debate
2. Biologics: Drawing (or Crossing) the line of Cost vs. Benefit: A Case in Oncology
3. Quality Adjusted Life Years (QALY’s) for Decision Making: Views from Canada & the US
4. Using Large Databases to Inform Decision Making: Experience in Three Health Care Systems
5. Real World Data for Decision Making: Moving Beyond Clinical Trials
6. Pharmacoeconomics of Pharmacogenomics
7. Pharmacoeconomics & Pricing: Now & After Health Care Reform
8. What is the Business Case for Quality Improvement Initiatives?
10. Biosimilars: Challenges and Opportunities for All.
11. Patient Reported Outcomes: Useful for Whom?

Current PE Forum Steering Committee members are:

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael S. Broder, MD, MSHS</td>
<td>Partnership for Health Analytic Research</td>
</tr>
<tr>
<td>Charles Daniels, RPh, PhD</td>
<td>UCSD, Skaggs School of Pharmacy</td>
</tr>
<tr>
<td>Mirta Millares, PharmD, FCSHP, FASHP</td>
<td>Kaiser Permanente</td>
</tr>
<tr>
<td>Jan D. Hirsch, RPh, PhD</td>
<td>UCSD, Skaggs School of Pharmacy</td>
</tr>
<tr>
<td>Anthony P. Morreale, PharmD, MBA, BCPS</td>
<td>Pharmacy Benefit Management</td>
</tr>
<tr>
<td>Michael Pollock</td>
<td>PPD</td>
</tr>
<tr>
<td>Robert Schoenhaus, PharmD</td>
<td>Sharp Healthcare</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>